| Abstract [eng] |
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder predominantly affecting apocrine gland-rich areas, characterized by recurrent inflammatory nodules, abscesses, fistulas, and scarring. It significantly impairs patients’ quality of life and presents considerable therapeutic challenges. This prospective study, conducted at the Centre of Dermatovenereology of Vilnius University Hospital Santaros Klinikos between March 2021 and June 2023, aimed to assess the relationship between HS risk factors, clinical characteristics, biological markers, and treatment efficacy. Data from 49 patients were analyzed. The findings indicate that diagnostic delays are common, particularly among female patients, often due to initial misdiagnoses. Obesity, smoking, and a family history of inflammatory or metabolic diseases were significantly associated with increased disease severity. The axillary region was most frequently affected, with the axillary-mammary phenotype being the most prevalent. Adalimumab, demonstrated a statistically significant reduction in inflammatory lesions, pain intensity, and quality-of-life impairment, with 47.6% of treated patients achieving HiSCR after one year. The results underscore the importance of early recognition, accurate diagnosis, and individualized treatment strategies in managing HS, with special attention to risk factors and associated conditions. |
